Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness

Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836 Lyon, France and Liège, Belgium – August 26, 2025 –  Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced it has …

Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine

Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine A Bill & Melinda Gates Foundation grant will be used to expand research and development of OVX836 in a wide range of seasonal and highly pathogenic influenza strains  Osivax continues evaluating OVX836 across several phase 2 clinical trials in healthy volunteers …